Sionna Therapeutics, Inc. Logo

Sionna Therapeutics, Inc.

Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.

SION | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
21 HICKORY DRIVE, SUITE 500, 2451 WALTHAM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative treatments for cystic fibrosis (CF). The company's mission is to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Its novel approach centers on stabilizing the protein's nucleotide-binding domain 1 (NBD1), which directly targets the defect caused by F508del, the most common CF-causing mutation. Sionna is advancing a pipeline of proprietary small molecule NBD1 stabilizers, such as SION-719, and a portfolio of complementary CFTR modulators designed to work synergistically. The ultimate goal is to restore CFTR function to near-normal levels, revolutionizing the treatment paradigm for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sionna Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sionna Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sionna Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Logo
Biotech firm developing cell therapies for regenerative medicine and immunotherapy applications.
United States of America
CELZ
CRESCENT BIOPHARMA, INC. Logo
A biotech company developing bispecific antibody therapies to treat solid tumors.
United States of America
CBIO
Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America
CRNX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America
CRSP
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France
ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America
CPIX
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan
4894

Talk to a Data Expert

Have a question? We'll get back to you promptly.